Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-3,200
Closed -$2.37M 581
2016
Q4
$2.37M Hold
3,200
0.47% 53
2016
Q3
$1.96M Buy
+3,200
New +$152K 0.29% 64
2016
Q1
Sell
-4,500
Closed -$2.37M 589
2015
Q4
$2.37M Hold
4,500
0.32% 54
2015
Q3
$2.27M Buy
4,500
+1,500
+50% +$61.6K 0.29% 62
2015
Q2
$1.99M Buy
+3,000
New +$132K 0.21% 64

Other funds holding BCE

Exane Derivatives's BCE Position: Q2 2022 in Review

Exane Derivatives sold out of BCE (BCE) in Q2 2022, closing a stake of 20,084 shares — an estimated $1.11M sold.

Exane Derivatives first reported a position in BCE in Q4 2015 and held it in 18 quarters. The position peaked at $7.54M in Q1 2019. 600 funds tracked by Wall St. Rank hold BCE as of Q2 2022.

  • Exane Derivatives reported no remaining BCE position as of Q2 2022 after selling out during the quarter.
  • Exane Derivatives sold 20,084 BCE shares in Q2 2022, an estimated $1.11M.
  • Exane Derivatives first reported a position in BCE in Q4 2015 and held it in 18 quarters.
  • Exane Derivatives's BCE position peaked at $7.54M in Q1 2019.
  • 600 funds tracked by Wall St. Rank held BCE as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.